Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.90 |
| ▸ | MAPT | P10636 | 6/20 | 0.83 |
| ▸ | NPC1 | O15118 | 3/20 | 0.83 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.80 |
| ▸ | RAB9A | P51151 | 2/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.66 |
| ▸ | APP | P05067 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | PDE4A | P27815 | 1/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.63 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL634386 | 1.00 | CHRNA7 (0.90) | CHRNA7MAPTNPC1L3MBTL1MEN1 | |
| SCHEMBL5088064 | 0.92 | CHRNA7 (0.81) | CHRNA7MAPTNPC1L3MBTL1MEN1 | |
| SCHEMBL5088071 | 0.92 | CHRNA7 (0.81) | CHRNA7MAPTNPC1L3MBTL1MEN1 | |
| SCHEMBL28390756 | 0.90 | MAPT (0.82) | CHRNA7MAPTNPC1L3MBTL1MEN1 | |
| SCHEMBL28390757 | 0.90 | MAPT (0.82) | CHRNA7MAPTNPC1L3MBTL1MEN1 | |
| SCHEMBL19183199 | 0.90 | APP (0.81) | CHRNA7MAPTNPC1L3MBTL1MEN1 | |
| SCHEMBL19183197 | 0.90 | APP (0.81) | CHRNA7MAPTNPC1L3MBTL1MEN1 | |
| SCHEMBL5139197 | 0.89 | NR1H4 (0.83) | CHRNA7MAPTNPC1L3MBTL1MEN1 | |
| SCHEMBL5139199 | 0.89 | NR1H4 (0.83) | CHRNA7MAPTNPC1L3MBTL1MEN1 | |
| SCHEMBL632910 | 0.89 | MAPT (0.81) | CHRNA7MAPTNPC1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-10 | — | — | US | disclosed |
| WO-2017132135-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-03 | — | — | WO | disclosed |
| EP-1888174-B1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | JOHNSON & JOHNSON CONSUMER (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20100279987-A1 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF | SALIOU CLAUDE | 2010-11-04 | — | — | US | disclosed |
| US-20100279987-A1 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF | SALIOU CLAUDE | 2010-11-04 | — | — | US | disclosed |
| US-7781410-B2 | Compositions containing chalcones and use thereof | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781410-B2 | Compositions containing chalcones and use thereof | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1888174-A1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | Johnson and Johnson Consumer Companies, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20080032938-A1 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF | JOHNSON & JOHNSON CONSUMER INC. | 2008-02-07 | — | — | US | disclosed |
| US-20080032938-A1 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF | JOHNSON & JOHNSON CONSUMER INC. | 2008-02-07 | — | — | US | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2006127539-A1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270614-A1 | Use of chalcones for the treatment of viral disorders | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | CHRNA7 684/4885MAPT 4566/4885NPC1 362/4885 |
| US-20080032938-A1 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF | CYP17A1, HSD17B7, CUTA | CHRNA7 4596/4885MAPT 2236/4885NPC1 344/4885 |
| US-20060270614-A1 | Use of chalcones for the treatment of viral disorders | HAVCR2, HMGB3, EIF2AK2 | CHRNA7 4811/4885MAPT 788/4885NPC1 324/4885 |
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | ESRRG, GPER1, ESR2 | CHRNA7 133/4885MAPT 4210/4885NPC1 4155/4885 |
| US-20100279987-A1 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF | CYP17A1, HSD17B7, CUTA | CHRNA7 4596/4885MAPT 2236/4885NPC1 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.